News for Harmony Biosciences Holdings, Inc. (HRMY)

Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Mixed analysts’ sentiments for the stock, following the presentation of preclinical data for BP1.15205. Headquartered in New Jersey, Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company engaged in the process of developing therapies for rare […]

Summary Harmony Biosciences Holdings Inc (HRMY) has announced that it will release its financial results for the second quarter of 2025 on Tuesday, August 5, 20

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2025 financial results on Tuesday, August 5, 2025, before

Harmony Biosciences (HRMY) to announce Q2 2025 financial results on August 5, 2025. An investor call and webcast are scheduled for 8:30 a.m. ET on the s

Harmony Biosciences Holdings, Inc. (HRMY) has received new attention from the financial sector as Truist Securities initiates coverage on the company with a "Bu

Truist has initiated coverage of Harmony Biosciences, symbolized by the ticker HRMY, assigning a Buy rating along with a price target of $48. The firm identifie

Summary Harmony Biosciences Holdings Inc (HRMY) has announced its participation in the virtual H.C. Wainwright "HCW@Home" series, scheduled for Thursday, July 1

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the 7 most undervalued pot stocks to buy according to analysts. On June 23, Mizuho reiterated its “Outperform” rating on Harmony and maintained a price target of $48. The reaffirmation followed Harmony’s presentation of preclinical data for BP1.15205 at the SLEEP 2025 conference. BP1.15205, an investigational orexin-2 […]

Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) is one of the most undervalued small-cap stocks to buy according to analysts. On June 11, Harmony Biosciences Holdings presented promising preclinical pharmacological data for BP1.15205, which is an investigational orexin 2 receptor (OX2R) agonist, at the 39th Annual Meeting of the Associated Professional Sleep Societies/APSS “SLEEP” in Seattle. The […]

We came across a bullish thesis on Harmony Biosciences Holdings, Inc. (HRMY) on Capital Curiosity’s Substack by Taylor Nichols. In this article, we will summarize the bulls’ thesis on HRMY. Harmony Biosciences Holdings, Inc. (HRMY)’s share was trading at $35.03 as of 5th June. HRMY’s trailing and forward P/E were 13.37 and 9.45 respectively according to Yahoo […]

We came across a bullish thesis on Harmony Biosciences Holdings, Inc. (HRMY) on Capital Curiosity’s Substack by Taylor Nichols. In this article, we will summarize the bulls’ thesis on HRMY.

Harmony Biosciences continues to deliver strong sales and earnings growth, driven by its flagship drug WAKIX and a potentially promising pipeline. Learn more on HRMY stock here.

Summary Harmony Biosciences Holdings Inc (HRMY) has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference, scheduled for Jun

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Goldman Sachs 46th

Harmony Biosciences (HRMY) set to participate in the Goldman Sachs 46th Annual Global Healthcare Conference. The event will feature a fireside chat on J

Harmony Biosciences Holdings (HRMY) receives a notable endorsement from Oppenheimer analyst Andreas Argyrides. The financial services firm assumes coverage with

On May 15, 2025, Mizuho analyst Graig Suvannavejh announced the maintenance of the "Outperform" rating for Harmony Biosciences Holdings, represented by the stoc

Mizuho has elevated its price target for Harmony Biosciences (HRMY) from $44 to $48, maintaining an Outperform rating after the company's first-quarter report.